MET and non-small cell lung carcinoma: Recently two new TKIs specifically targeting EGFR exon 20 in-frame insertions, mobocertinib (21) and poziotinib (22) and a bi-specific monoclonal antibody targeting MET-EGFR, amivantamab (23), showed very encouraging clinical activity in EGFR exon-20 insertion-mutation NSCLC, although they are probably less well tolerated compared to Osimertinib.